The identification to transcription factor activated by Akt and the investigation for the relation between the transcription factor and antidepressant effect.

2014 Fiscal Year Final Research Report

• Project/Area Number: 25870844
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Psychiatric science; Medical pharmacy
• Research Institution: St. Marianna University School of Medicine
• Principal Investigator: Nakano Miho 聖マリアンナ医科大学, 医学部, 助教 (90621574)
• Project Period (FY): 2013-04-01 – 2015-03-31
• Keywords: Akt / 抗うつ薬 / BDNF

Outline of Final Research Achievements

The expression of brain-derived neurotrophic factor (BDNF) may be a downstream target of a variety of antidepressant treatments, and selective serotonin reuptake inhibitors (SSRIs) are used clinically for the treatment of depression. BDNF binds to and activates tyrosine kinases receptor (TrkB) to exert its effects. TrkB, after activation by ligands, stimulates phosphoinositide 3-kinase (PI3K). This study demonstrates that fluvoxamine treatment rapidly increased phosphorylation of Akt-1. And BDNF activated Akt-1 phosphorylation by the TrkB/ PI3K/Akt-1 pathway. We conclude that the phosphorylation of Akt-1, downstream of PI3K, was the key to their antidepressant effects.
We developed the milnaciplan, SNRI, resistant HT22 cell, and detected the changed protein by the proteomics method. We detected some proteins, tRNA ligase, glucose-regulated protein, histone-binding protein compared with control.

Free Research Field

神経精神医学